TCR2 Therapeutics Inc. announced it has entered into a Cooperative Research and Development Agreement with NCI to collaborate on the use of TCR2’s proprietary T cell receptor Fusion Construct T cells as a cancer therapeutic agent against mesothelin in the Company’s ongoing phase I/II trial of TC-210.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe